Show simple item record

dc.contributor.authorOrrem, Hilde L.
dc.contributor.authorNilsson, Per H.
dc.contributor.authorPischke, Søren Erik
dc.contributor.authorGrindheim, Guro
dc.contributor.authorGarred, Peter
dc.contributor.authorSeljeflot, Ingebjørg
dc.contributor.authorHusebye, Trygve
dc.contributor.authorAukrust, Pål
dc.contributor.authorYndestad, Arne
dc.contributor.authorAndersen, Geir Ø.
dc.contributor.authorBarratt-Due, Andreas
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2018-11-06T12:40:40Z
dc.date.available2018-11-06T12:40:40Z
dc.date.issued2018-02-09
dc.description.abstractAims: Heart failure (HF) is an impending complication to myocardial infarction. We hypothesized that the degree of complement activation reflects severity of HF following acute myocardial infarction. <br> <br> Methods and results: The LEAF trial (LEvosimendan in Acute heart Failure following myocardial infarction) evaluating 61 patients developing HF within 48 h after percutaneous coronary intervention-treated ST-elevation myocardial infarction herein underwent a post hoc analysis. Blood samples were drawn from inclusion to Day 5 and at 42-day follow-up, and biomarkers were measured with enzyme immunoassays. Regional myocardial contractility was measured by echocardiography as wall motion score index (WMSI). The cardiogenic shock group (n = 9) was compared with the non-shock group (n = 52). Controls (n = 44) were age-matched and sex-matched healthy individuals. C4bc, C3bc, C3bBbP, and sC5b-9 were elevated in patients at inclusion compared with controls (P < 0.01). The shock group had higher levels compared with the non-shock group for all activation products except C3bBbP (P < 0.05). At Day 42, all products were higher in the shock group (P < 0.05). In the shock group, sC5b-9 correlated significantly with WMSI at baseline (r = 0.68; P = 0.045) and at Day 42 (r = 0.84; P = 0.036). Peak sC5b-9 level correlated strongly with WMSI at Day 42 (r = 0.98; P = 0.005). Circulating endothelial cell activation markers sICAM-1 and sVCAM-1 were higher in the shock group during the acute phase (P < 0.01), and their peak levels correlated with sC5b-9 peak level in the whole HF population (r = 0.32; P = 0.014 and r = 0.30; P = 0.022, respectively). <br> <br> Conclusions: Complement activation discriminated cardiogenic shock from non-shock in acute ST-elevation myocardial infarction complicated by HF and correlated with regional contractility and endothelial cell activation, suggesting a pathogenic role of complement in this conditionen_US
dc.descriptionSource at <a href=https://doi.org/10.1002/ehf2.12266>https://doi.org/10.1002/ehf2.12266 </a>.en_US
dc.identifier.citationOrrem, H. L., Nilsson, P. H., Pischke, S. E., Grindheim, G., Garred, P., Seljeflot, I., Husebye, T., Aukrust, P., Yndestad, A., Andersen, G. Ø., Barratt-Due, A., … Mollnes, T. E. (2018). Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock. ESC heart failure, 5, 3, 292-301. https://doi.org/10.1002/ehf2.12266en_US
dc.identifier.cristinIDFRIDAID 1616256
dc.identifier.doi10.1002/ehf2.12266
dc.identifier.issn2055-5822
dc.identifier.urihttps://hdl.handle.net/10037/14100
dc.language.isoengen_US
dc.publisherWiley Open Accessen_US
dc.relation.journalESC Heart Failure
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/602699/EU/Disarming the intravascular innate immune response to improve treatment modalities for chronic kidney disease//.en_US
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Cardiology: 771en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771en_US
dc.subjectComplement activationen_US
dc.subjectInflammationen_US
dc.subjectMyocardial infarctionen_US
dc.subjectAcute heart failureen_US
dc.subjectCardiogenic shocken_US
dc.subjectWall motion score indexen_US
dc.titleAcute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shocken_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record